François Wilhelm

1.4k total citations
64 papers, 796 citations indexed

About

François Wilhelm is a scholar working on Hematology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, François Wilhelm has authored 64 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 23 papers in Oncology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in François Wilhelm's work include Acute Myeloid Leukemia Research (22 papers), Chronic Myeloid Leukemia Treatments (14 papers) and HER2/EGFR in Cancer Research (9 papers). François Wilhelm is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Chronic Myeloid Leukemia Treatments (14 papers) and HER2/EGFR in Cancer Research (9 papers). François Wilhelm collaborates with scholars based in United States, Netherlands and India. François Wilhelm's co-authors include Anthony W. Norman, Manoj Maniar, Greetje J. de Grooth, Jan Albert Kuivenhoven, Mieke D. Trip, Anke H.E.M. Klerkx, John J.P. Kastelein, Azra Raza, Chen Ren and Peter L. Greenberg and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

François Wilhelm

62 papers receiving 770 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
François Wilhelm United States	16	270	264	220	173	122	64	796
Minoru Shigekawa Japan	19	502 1.9×	315 1.2×	107 0.5×	230 1.3×	82 0.7×	63	1.2k
Tomohiko Sakabe Japan	17	475 1.8×	248 0.9×	46 0.2×	163 0.9×	60 0.5×	43	991
Ruri Ohki Japan	13	365 1.4×	153 0.6×	64 0.3×	155 0.9×	34 0.3×	18	743
Lichen Teng China	17	270 1.0×	109 0.4×	228 1.0×	79 0.5×	24 0.2×	63	1.0k
Wenwen Chien United States	20	822 3.0×	250 0.9×	60 0.3×	59 0.3×	161 1.3×	29	1.1k
Laura A. Pike United States	13	401 1.5×	313 1.2×	60 0.3×	29 0.2×	124 1.0×	26	743
Hitoyasu Futami Japan	16	330 1.2×	420 1.6×	43 0.2×	115 0.7×	65 0.5×	41	869
Yasuhito Fujisaka Japan	17	247 0.9×	481 1.8×	78 0.4×	56 0.3×	25 0.2×	51	885
Holger Fritsch Germany	18	588 2.2×	510 1.9×	226 1.0×	61 0.4×	465 3.8×	34	1.1k
Florence Namour Belgium	14	188 0.7×	194 0.7×	99 0.5×	39 0.2×	47 0.4×	29	646

Countries citing papers authored by François Wilhelm

Since Specialization

Citations

This map shows the geographic impact of François Wilhelm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by François Wilhelm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites François Wilhelm more than expected).

Fields of papers citing papers by François Wilhelm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by François Wilhelm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by François Wilhelm. The network helps show where François Wilhelm may publish in the future.

Co-authorship network of co-authors of François Wilhelm

This figure shows the co-authorship network connecting the top 25 collaborators of François Wilhelm. A scholar is included among the top collaborators of François Wilhelm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with François Wilhelm. François Wilhelm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Faltas, Bishoy M., David M. Goldenberg, Allyson J. Ocean, et al.. (2015). Sacituzumab Govitecan, a Novel Antibody–Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma. Clinical Genitourinary Cancer. 14(1). e75–e79. 81 indexed citations

Bowles, Daniel W., Jennifer R. Diamond, Elaine T. Lam, et al.. (2014). Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies. Clinical Cancer Research. 20(6). 1656–1665. 54 indexed citations

Digumarti, Raghunadharao, et al.. (2014). Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer. Indian Journal of Cancer. 51(1). 40–40. 3 indexed citations

Anderson, Ryan T., Stephen B. Keysar, Daniel W. Bowles, et al.. (2013). The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas. Molecular Cancer Therapeutics. 12(10). 1994–2005. 20 indexed citations

Raza, Azra, Benjamin Tycko, Sang‐Min Lee, et al.. (2013). Oral Rigosertib (ON 01910.Na) Treatment Produces An Encouraging Rate Of Transfusion Independence In Lower Risk Myelodysplastic Syndromes (MDS) Patients; A Genomic Methylation Profile Is Associated With Responses. Blood. 122(21). 2745–2745. 6 indexed citations

Wee, Wen, Wells A. Messersmith, Grace K. Dy, et al.. (2012). Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer. Clinical Cancer Research. 18(7). 2048–2055. 42 indexed citations

Olnes, Matthew J., Aarthi Shenoy, Barbara Weinstein, et al.. (2012). Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leukemia Research. 36(8). 982–989. 32 indexed citations

Navada, Shyamala, Rosalie Odchimar-Reissig, E. P. Reddy, et al.. (2012). Evaluation of Rigosertib in Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I/II Study. Blood. 120(21). 3794–3794. 4 indexed citations

Fan, Alice C., Liwen Xu, Kunju Sridhar, et al.. (2011). A Novel Nano-Immunoassay (NIA) Reveals Inhibition of PI3K and MAPK Pathways in CD34+ Bone Marrow Cells of Patients with Myelodysplastic Syndrome (MDS) Treated with the Multi-Kinase Inhibitor On 01910.Na (Rigosertib),. Blood. 118(21). 3808–3808. 3 indexed citations

10.

Seetharam, Mahesh, Alice C. Fan, Mai Tran, et al.. (2011). Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leukemia Research. 36(1). 98–103. 43 indexed citations

11.

Chaudhary, Imran, Lakshmi Rajdev, Umang Swami, et al.. (2010). Phase I dose-escalation study of ON 01910.Na in combination with oxaliplatin in patients with advanced solid tumors.. Journal of Clinical Oncology. 28(15_suppl). e13133–e13133. 1 indexed citations

12.

Silverman, Lewis R., Rosalie Odchimar-Reissig, Shyamala Navada, et al.. (2009). Effects of a Novel Benzyl Styryl Sulfone Derivative ON 01910.Na On the Myelodysplastic Syndrome (MDS) Derived Clone in Patients Relapsing Following Response to Azacitidine (AzaC) Therapy.. Blood. 114(22). 4839–4839. 2 indexed citations

13.

Glaspy, John A., Veena Charu, Donghan Luo, et al.. (2009). Initiation of epoetin‐α therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy. Cancer. 115(5). 1121–1131. 7 indexed citations

14.

Raza, Azra, et al.. (2009). Initial Evaluation of a 48-h Continuous Intravenous Infusion Weekly Regimen of ON 01910.Na in Advanced Myelodysplastic Syndrome (MDS).. Blood. 114(22). 3815–3815. 2 indexed citations

15.

Xie, John, et al.. (2007). An extended maintenance dosing regimen of epoetin alfa 80,000 U every 3 weeks in anemic patients with cancer receiving chemotherapy. Supportive Care in Cancer. 15(12). 1385–1392. 5 indexed citations

16.

Gregory, Stephanie A., et al.. (2007). An Extended Dosing Regimen of Epoetin Alfa 60,000 Units Every 2 Weeks in Anemic Patients with Cancer Receiving Chemotherapy. PubMed. 4(4). 225–232. 1 indexed citations

17.

Williams, Denise, et al.. (2006). An Open-Label Pilot Study to Evaluate a Flexible Dosing Regimen of Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: 60,000 Units Weekly Followed by 60,000 Units Every 2 Weeks. PubMed. 4(1). 56–62. 6 indexed citations

18.

Henry, David H., Lucio Gordan, Veena Charu, et al.. (2006). Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia. Current Medical Research and Opinion. 22(7). 1403–1413. 21 indexed citations

19.

Kuivenhoven, Jan Albert, Greetje J. de Grooth, Anke H.E.M. Klerkx, et al.. (2005). Effectiveness of Inhibition of Cholesteryl Ester Transfer Protein by JTT-705 in Combination With Pravastatin in Type II Dyslipidemia. The American Journal of Cardiology. 95(9). 1085–1088. 136 indexed citations

20.

Wilhelm, François, E. Mayer, & Anthony W. Norman. (1984). Biological activity assessment of the 26,23-lactones of 1,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 and their binding properties to chick intestinal receptor and plasma vitamin D binding protein. Archives of Biochemistry and Biophysics. 233(2). 322–329. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact